The Man Who'd Rather Die Than Vaccinate His Kids Might Run U.S. Emergency Health
A nominee for the office that coordinates America's pandemic response has called mRNA vaccines "reckless" and promoted the debunked vaccines-autism link. Public health experts are sounding alarms, and vaccine makers are quietly rethinking their U.S. strategies.
Imagine you're hiring a lifeguard. The top candidate looks great on paper, but there's one catch: he's posted online that he'd "rather perish" than let his own children go near the water.
That's roughly the situation playing out at the Department of Health and Human Services right now.
Meet Sean Kaufman
Sean Kaufman has been nominated to serve as Assistant Secretary for Preparedness and Response (ASPR), the person who'd oversee America's playbook for pandemics, bioterror events, and natural disasters. Think of ASPR as the country's emergency health quarterback. When the next crisis hits, this office calls the plays.
Kaufman's resume isn't the issue. His social media history is.
In a now-deleted LinkedIn post from May 2025, Kaufman argued against giving hepatitis B vaccines to newborns. He then wrote: "And before you dismiss all this as 'antivaxxer nonsense,' consider this: autism." He proceeded to make the case that hepatitis B shots might be driving rising autism rates, a claim that has been studied extensively and debunked by large-scale research over decades.
In a separate video from the same month, he characterized hepatitis B as a disease mainly affecting people engaging in "risky sexual activity or sharing needles," downplaying the risk to newborns. And in other posts, he described offering mRNA COVID-19 vaccines as "reckless" and called himself "a father of three who would rather perish than have any one of his children receive an injection where the risks soundly outweigh the benefits gained."
This is the person nominated to coordinate America's emergency health response.
Not an Isolated Hire
Kaufman's nomination doesn't exist in a vacuum. It fits into a broader pattern at HHS under Secretary Robert F. Kennedy Jr., who has spent decades promoting vaccine skepticism through his organization, Children's Health Defense.
Since taking over HHS, Kennedy has already made sweeping changes. In June 2025, he fired all 17 members of the Advisory Committee on Immunization Practices (ACIP), the expert panel that guides which vaccines Americans should get and when. He replaced many of them with people who share his skepticism. The reconstituted committee then voted to delay or restrict the hepatitis B birth dose and ban thimerosal (a preservative) from flu shots.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
By January 2026, HHS issued a memo that slashed the number of diseases targeted by routine childhood vaccines from 17 to 11. Rotavirus, COVID-19, influenza, hepatitis A, hepatitis B, and meningococcal vaccines were all downgraded from "routine" to "shared clinical decision-making," which is bureaucratic speak for "optional if your doctor brings it up." In practice, that means fewer kids get vaccinated.
A court stepped in this March, freezing most of these changes and temporarily restoring the pre-June 2025 schedule. But the confusion has already been sown.
The Experts Are Not Mincing Words
Public health leaders have responded with something close to panic.
Dr. Paul Offit of Children's Hospital of Philadelphia called Kennedy's confirmation "a sad day for children" and "a sad day for the public's health," describing the situation as putting a "science denialist, conspiracy theorist, and virulent anti-vaccine activist" in charge of the nation's largest public health agency.
Dr. Tina Tan, president of the Infectious Diseases Society of America, was equally direct. She called the reconstituted ACIP's moves "politically motivated actions that are not based on science" and warned that raising safety questions without supporting data "casts doubt on vaccination, which can further drive down confidence in vaccines."
Leaders from the American College of Physicians, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians issued a joint warning: "When immunization rates drop, significant outbreaks return. History has shown us that when trust in science falters, preventable disease rapidly spreads and people suffer needlessly."
All of this is happening while a measles outbreak is actively underway and routine childhood vaccination rates are already declining.
Wall Street's Uncomfortable Shrug
You might expect vaccine stocks to crater on this kind of news. They haven't, at least not dramatically. When Kennedy fired ACIP, the market reaction was surprisingly muted: GSK dropped about 1%, Sanofi dipped 0.2%, and AstraZeneca and BioNTech actually ticked up.
But the calm surface hides deeper currents. Leerink analyst Daina Graybosch warned that a skeptic-led ACIP could raise evidence requirements and development costs for future vaccines, while adversely affecting recommendations for existing ones. RBC flagged U.S. regulatory uncertainty as one of the largest concerns for the entire biotech sector, noting that inconsistency in vaccine regulation has "challenged investability."
The numbers tell a clearer story over time. Pfizer's COVID-19 vaccine sales plunged 59% year-over-year in Q1, and the franchise is expected to decline another 23% in 2026 to roughly $5 billion. Pfizer CEO Albert Bourla has publicly criticized what he calls "anti-vaccine policies" at HHS. Moderna, meanwhile, is hedging by splitting its 2026 COVID vaccine revenue evenly between U.S. and international markets, a deliberate pivot away from domestic dependence.
GSK has fared better, with vaccine sales climbing 4% in Q1, powered by a 20% surge in Shingrix (its shingles vaccine). Adult vaccines and international markets are becoming the lifeboats for companies that once relied heavily on American childhood immunization programs.
The Bigger Picture
What's unfolding isn't just a policy debate. It's a slow-motion restructuring of how America thinks about vaccines.
The FDA has already narrowed COVID-19 vaccine authorizations so that healthy adults under 65 and young children can no longer easily get the shots. The agency's new vaccine chief, Vinay Prasad, has called for longer clinical trials and stricter efficacy standards for routine updates like the annual flu shot. HHS canceled approximately $500 million in mRNA vaccine contracts and redirected the funding toward whole-virus technology.
For biotech investors, the calculus is shifting. Capital is quietly flowing toward oncology, rare disease, and cell therapy, where the regulatory path looks more predictable. Vaccine-focused companies face what analysts describe as a "higher volatility regime," where every ACIP meeting or FDA communication can swing stock prices.
Why This Nomination Matters More Than You Think
ASPR isn't a sleepy bureaucratic post. This is the office that coordinated the federal response to COVID-19, managed the Strategic National Stockpile, and oversaw billions in emergency medical countermeasure contracts. The person in this chair decides which vaccines, therapeutics, and supplies get stockpiled for the next pandemic.
Putting someone who has called mRNA vaccination "reckless" in charge of pandemic preparedness is like hiring a fire chief who thinks smoke detectors are overrated. Maybe nothing burns down. But if it does, you really want someone who believes in the equipment.
The Senate hasn't voted yet. But the nomination alone sends a signal that reverberates through public health agencies, vaccine boardrooms, and the investment community: the people making life-or-death preparedness decisions may not trust the tools they'd need to use.
Clinical & Regulatory
4 min read
The Drug That Worked Perfectly and Still Failed
AstraZeneca and Ionis' gene-silencing drug eplontersen did everything right biologically in a massive ATTR cardiomyopathy trial, yet still failed to keep patients alive or out of the hospital. The reason why could reshape how the entire industry thinks about combination therapy.
